The previous edition of the consensus guidelines of the International Workshop on Chronic
Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by …

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Herein, we present the long-term follow-up of the randomized E1912 trial comparing the
long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and …

We previously reported durable responses and manageable safety of ibrutinib from a 3-year
follow-up of treatment-naïve (TN) older patients (≥ 65 years of age) and relapsed/refractory …

Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in
the past two decades have led to the development of new prognostic tools and novel …

Accurate identification of patients likely to achieve long-progression-free survival (PFS) after
chemoimmunotherapy is essential given the availability of less toxic alternatives, such as …

The term 'immunogenic cell death'(ICD) denotes an immunologically unique type of
regulated cell death that enables, rather than suppresses, T cell-driven immune responses …

The somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable
(IGHV) gene is a critical biomarker for assessing the prognosis of patients with chronic …

The expression “immunogenic cell death”(ICD) refers to a functionally unique form of cell
death that facilitates (instead of suppressing) a T cell-dependent immune response specific …

The traditional view holds that apoptosis is non-immunogenic and does not induce an
inflammatory response. However, recent studies have suggested that certain …